FY2025 EPS Estimates for AQST Boosted by Cantor Fitzgerald

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a report released on Tuesday, August 19th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($0.56) for the year, up from their previous forecast of ($0.64). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. Cantor Fitzgerald also issued estimates for Aquestive Therapeutics’ FY2026 earnings at ($0.57) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

A number of other equities analysts have also recently issued reports on AQST. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Zacks Research upgraded Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, Oppenheimer began coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They set an “outperform” rating and a $7.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.14.

Aquestive Therapeutics Trading Up 0.8%

Shares of AQST opened at $3.88 on Thursday. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80. The stock has a market cap of $386.91 million, a P/E ratio of -5.54 and a beta of 1.99. The stock’s 50-day moving average price is $3.79 and its two-hundred day moving average price is $3.17.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at approximately $33,000. BNP Paribas Financial Markets raised its position in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares during the last quarter. Jane Street Group LLC acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at approximately $217,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after buying an additional 2,649 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Aquestive Therapeutics by 16.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock valued at $106,000 after buying an additional 4,557 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.